| | | | | | | | | | | | | | | | |
| |
![Collapse](/DXR.axd?r=1_87-p7f1t) | Issue Date FY: 2024 ( Subtotal = $423,386,208 ) (Continued on the next page) |
| 2024 | 2024 | THE GENERAL HOSPITAL CORPORATION | 55 FRUIT ST | BOSTON | MA | 02114-2621 | SUFFOLK | USA | R01AI138790 | Optimizing HIV-specific T-cell responses by therapeutic vaccination | 000 | 5 | NIH | 1/22/2024 | $136,948 |
| 2024 | 2024 | THE GENERAL HOSPITAL CORPORATION | 55 FRUIT ST | BOSTON | MA | 02114-2621 | SUFFOLK | USA | R35HL139598 | Imaging organ system interfaces in ischemic heart disease | 001 | 7 | NIH | 6/19/2024 | $78,793 |
| 2024 | 2024 | THE GENERAL HOSPITAL CORPORATION | 55 FRUIT ST | BOSTON | MA | 02114-2621 | SUFFOLK | USA | R35HL139598 | Imaging organ system interfaces in ischemic heart disease | 000 | 7 | NIH | 1/29/2024 | $886,430 |
| 2024 | 2024 | THE GENERAL HOSPITAL CORPORATION | 55 FRUIT ST | BOSTON | MA | 02114-2621 | SUFFOLK | USA | R01CA260890 | Synergistic combinatorial DNA damage response/repair inhibition and Sacituzumab Govitecan in triple-negative breast cancer | 001 | 3 | NIH | 4/22/2024 | $27,989 |
| 2024 | 2024 | THE GENERAL HOSPITAL CORPORATION | 55 FRUIT ST | BOSTON | MA | 02114-2621 | SUFFOLK | USA | R01CA260890 | Synergistic combinatorial DNA damage response/repair inhibition and Sacituzumab Govitecan in triple-negative breast cancer | 000 | 3 | NIH | 12/29/2023 | $503,805 |
| 2024 | 2024 | THE GENERAL HOSPITAL CORPORATION | 55 FRUIT ST | BOSTON | MA | 02114-2621 | SUFFOLK | USA | R03AG087483 | Next generation metabolic imaging of the effect of exercise on mitochondrial function in Alzheimer's disease | 000 | 1 | NIH | 7/2/2024 | $332,096 |
| 2024 | 2024 | THE GENERAL HOSPITAL CORPORATION | 55 FRUIT ST | BOSTON | MA | 02114-2621 | SUFFOLK | USA | R00AG066819 | Controlling oscillations to treat Alzheimers disease targeting the basal forebrain parvalbuminsystem | 000 | 3 | NIH | 7/22/2024 | $248,966 |
| 2024 | 2024 | THE GENERAL HOSPITAL CORPORATION | 55 FRUIT ST | BOSTON | MA | 02114-2621 | SUFFOLK | USA | R01AI179917 | Vaccine- and infection-derived correlates of protection for cholera | 000 | 1 | NIH | 7/22/2024 | $663,723 |
| 2024 | 2024 | THE GENERAL HOSPITAL CORPORATION | 55 FRUIT ST | BOSTON | MA | 02114-2621 | SUFFOLK | USA | OT2HL161841 | Interactive Data Portals and Robust Analytic Tools to Wrap PASC Cohorts (iDRAW) OTA-21-015A | 000 | 1 | NIH | 1/2/2024 | $25,000,000 |
| 2024 | 2024 | THE GENERAL HOSPITAL CORPORATION | 55 FRUIT ST | BOSTON | MA | 02114-2621 | SUFFOLK | USA | T2537602 | Addiction Medicine Fellowship | 01 | 5 | HRSA | 7/22/2024 | $24,612 |
| 2024 | 2024 | THE GENERAL HOSPITAL CORPORATION | 55 FRUIT ST | BOSTON | MA | 02114-2621 | SUFFOLK | USA | T2537602 | Addiction Medicine Fellowship | 00 | 5 | HRSA | 5/24/2024 | $799,955 |
| 2024 | 2024 | THE GENERAL HOSPITAL CORPORATION | 55 FRUIT ST | BOSTON | MA | 02114-2621 | SUFFOLK | USA | R01CA280972 | Colorectal Cancer Screening with Optical Coherence Tomography | 000 | 1 | NIH | 7/22/2024 | $760,897 |
| 2024 | 2024 | THE GENERAL HOSPITAL CORPORATION | 55 FRUIT ST | BOSTON | MA | 02114-2621 | SUFFOLK | USA | K24AT011760 | Mentoring in technology enhanced mind body and lifestyle interventions | 000 | 3 | NIH | 12/14/2023 | $182,118 |
| 2024 | 2024 | THE GENERAL HOSPITAL CORPORATION | 55 FRUIT ST | BOSTON | MA | 02114-2621 | SUFFOLK | USA | R01MH138255 | PrEP My Way: A hybrid type 1 clinical effectiveness-implementation trial to promote PrEP persistence among young Kenyan women | 000 | 1 | NIH | 7/23/2024 | $616,099 |
| 2024 | 2024 | THE GENERAL HOSPITAL CORPORATION | 55 FRUIT ST | BOSTON | MA | 02114-2621 | SUFFOLK | USA | S10OD034375 | Versatile high-throughput Alinity ci assay platform to support multiple laboratory animal users | 000 | 1 | NIH | 7/19/2024 | $252,500 |
| 2024 | 2024 | THE GENERAL HOSPITAL CORPORATION | 55 FRUIT ST | BOSTON | MA | 02114-2621 | SUFFOLK | USA | S10OD034375 | Versatile high-throughput Alinity ci assay platform to support multiple laboratory animal users | 001 | 1 | NIH | 7/23/2024 | $0 |
| 2024 | 2024 | THE GENERAL HOSPITAL CORPORATION | 55 FRUIT ST | BOSTON | MA | 02114-2621 | SUFFOLK | USA | R21AI173732 | Lipid shuttling in memory Th2 cell fate and function in allergic asthma | 001 | 2 | NIH | 5/10/2024 | $25,200 |
| 2024 | 2024 | THE GENERAL HOSPITAL CORPORATION | 55 FRUIT ST | BOSTON | MA | 02114-2621 | SUFFOLK | USA | R21AI173732 | Lipid shuttling in memory Th2 cell fate and function in allergic asthma | 000 | 2 | NIH | 10/26/2023 | $226,800 |
| 2024 | 2024 | THE GENERAL HOSPITAL CORPORATION | 55 FRUIT ST | BOSTON | MA | 02114-2621 | SUFFOLK | USA | R21CA286215 | A multimodal single-cell approach to developing personalized combinatorial treatments for glioblastoma | 000 | 1 | NIH | 1/22/2024 | $249,832 |
| 2024 | 2024 | THE GENERAL HOSPITAL CORPORATION | 55 FRUIT ST | BOSTON | MA | 02114-2621 | SUFFOLK | USA | R33CA281794 | Nano-CRISPR extracellular vesicle sensing system for longitudinal tumor monitoring | 000 | 1 | NIH | 7/19/2024 | $415,830 |
| 2024 | 2024 | THE GENERAL HOSPITAL CORPORATION | 55 FRUIT ST | BOSTON | MA | 02114-2621 | SUFFOLK | USA | R03HL171347 | Protective role of B cells in hyperoxic lung injury | 000 | 1 | NIH | 7/17/2024 | $124,536 |
| 2024 | 2024 | THE GENERAL HOSPITAL CORPORATION | 55 FRUIT ST | BOSTON | MA | 02114-2621 | SUFFOLK | USA | R01EY033709 | Cellular and molecular mechanisms of AIM2 and NLRP3 inflammasome activation in age-related macular degeneration | 000 | 2 | NIH | 1/22/2024 | $483,730 |
| 2024 | 2024 | THE GENERAL HOSPITAL CORPORATION | 55 FRUIT ST | BOSTON | MA | 02114-2621 | SUFFOLK | USA | R01NS126691 | Development, Function, and Dysfunction of Gastrointestinal Tract-Innervating Dorsal Root Ganglia Neurons in Autism Spectrum Disorder | 001 | 2 | NIH | 4/9/2024 | $27,296 |
| 2024 | 2024 | THE GENERAL HOSPITAL CORPORATION | 55 FRUIT ST | BOSTON | MA | 02114-2621 | SUFFOLK | USA | R01NS126691 | Development, Function, and Dysfunction of Gastrointestinal Tract-Innervating Dorsal Root Ganglia Neurons in Autism Spectrum Disorder | 000 | 2 | NIH | 1/19/2024 | $350,943 |
| 2024 | 2024 | THE GENERAL HOSPITAL CORPORATION | 55 FRUIT ST | BOSTON | MA | 02114-2621 | SUFFOLK | USA | R01CA295109 | Title: Multi-Site Randomized Controlled Trial of a Novel Digital Application (SHIFT) to Improve Outcomes for Hematopoietic Stem Cell Transplant Survivors | 000 | 1 | NIH | 7/17/2024 | $602,526 |
| 2024 | 2024 | THE GENERAL HOSPITAL CORPORATION | 55 FRUIT ST | BOSTON | MA | 02114-2621 | SUFFOLK | USA | R21GM148826 | Optimizing methods of clinical sample processing for scRNA-seq and mechanistic studies in sepsis to enable reliable, reproducible, and high-yield multi-center collection efforts | 000 | 2 | NIH | 12/18/2023 | $179,666 |
| 2024 | 2024 | THE GENERAL HOSPITAL CORPORATION | 55 FRUIT ST | BOSTON | MA | 02114-2621 | SUFFOLK | USA | R21EB031185 | Deep Learning Reconstruction for Rapid Multi-Component Relaxometry | 001 | 3 | NIH | 5/27/2024 | $25,219 |
| 2024 | 2024 | THE GENERAL HOSPITAL CORPORATION | 55 FRUIT ST | BOSTON | MA | 02114-2621 | SUFFOLK | USA | R21EB031185 | Deep Learning Reconstruction for Rapid Multi-Component Relaxometry | 000 | 3 | NIH | 12/28/2023 | $226,971 |
| 2024 | 2024 | THE GENERAL HOSPITAL CORPORATION | 55 FRUIT ST | BOSTON | MA | 02114-2621 | SUFFOLK | USA | R01AI177414 | Staphylococcal protease-mediated epithelial barrier perturbation and allergen sensitization | 001 | 1 | NIH | 2/1/2024 | $0 |
| 2024 | 2024 | THE GENERAL HOSPITAL CORPORATION | 55 FRUIT ST | BOSTON | MA | 02114-2621 | SUFFOLK | USA | R01AI177414 | Staphylococcal protease-mediated epithelial barrier perturbation and allergen sensitization | 000 | 1 | NIH | 1/18/2024 | $589,351 |
| 2024 | 2024 | THE GENERAL HOSPITAL CORPORATION | 55 FRUIT ST | BOSTON | MA | 02114-2621 | SUFFOLK | USA | R01AI175345 | Antibody mediated immunity against Klebsiella pneumoniae | 001 | 1 | NIH | 5/24/2024 | $69,680 |
| 2024 | 2024 | THE GENERAL HOSPITAL CORPORATION | 55 FRUIT ST | BOSTON | MA | 02114-2621 | SUFFOLK | USA | R01AI175345 | Antibody mediated immunity against Klebsiella pneumoniae | 000 | 1 | NIH | 11/30/2023 | $660,621 |
| 2024 | 2024 | THE GENERAL HOSPITAL CORPORATION | 55 FRUIT ST | BOSTON | MA | 02114-2621 | SUFFOLK | USA | R01NS131347 | Comparative effectiveness of EEG-guided anti-seizure treatment in acute brain injury | 000 | 1 | NIH | 11/30/2023 | $698,062 |
| 2024 | 2024 | THE GENERAL HOSPITAL CORPORATION | 55 FRUIT ST | BOSTON | MA | 02114-2621 | SUFFOLK | USA | K01AG084820 | Neurogenetic contributions to the spread of tau pathology in sporadic early-onset Alzheimer's disease | 000 | 1 | NIH | 11/28/2023 | $129,075 |
| 2024 | 2024 | THE GENERAL HOSPITAL CORPORATION | 55 FRUIT ST | BOSTON | MA | 02114-2621 | SUFFOLK | USA | R01AI174276 | Eliminating the Immunogenicity of AAV Vectored HIV Antibody Delivery | 000 | 1 | NIH | 1/8/2024 | $350,000 |
| 2024 | 2024 | THE GENERAL HOSPITAL CORPORATION | 55 FRUIT ST | BOSTON | MA | 02114-2621 | SUFFOLK | USA | R01AI174276 | Eliminating the Immunogenicity of AAV Vectored HIV Antibody Delivery | 000 | 1 | NIH | 1/8/2024 | $472,056 |
| 2024 | 2024 | THE GENERAL HOSPITAL CORPORATION | 55 FRUIT ST | BOSTON | MA | 02114-2621 | SUFFOLK | USA | K01NS134784 | Development of in Vivo Base Editing as a Genetic Treatment for Spinal Muscular Atrophy | 001 | 1 | NIH | 2/5/2024 | $0 |
| 2024 | 2024 | THE GENERAL HOSPITAL CORPORATION | 55 FRUIT ST | BOSTON | MA | 02114-2621 | SUFFOLK | USA | K01NS134784 | Development of in Vivo Base Editing as a Genetic Treatment for Spinal Muscular Atrophy | 000 | 1 | NIH | 1/17/2024 | $244,458 |
| 2024 | 2024 | THE GENERAL HOSPITAL CORPORATION | 55 FRUIT ST | BOSTON | MA | 02114-2621 | SUFFOLK | USA | K99CA286969 | Breaching the Tumor-Immune Mechanical Barrier for Optimal Antitumor Immunity | 000 | 1 | NIH | 1/17/2024 | $176,040 |
| 2024 | 2024 | THE GENERAL HOSPITAL CORPORATION | 55 FRUIT ST | BOSTON | MA | 02114-2621 | SUFFOLK | USA | R01GM152809 | Automated technology for the preservation of Drosophila embryos | 000 | 1 | NIH | 1/23/2024 | $567,229 |
| 2024 | 2024 | THE GENERAL HOSPITAL CORPORATION | 55 FRUIT ST | BOSTON | MA | 02114-2621 | SUFFOLK | USA | R01EB034197 | Plug-and-play Hyperpolarized MRI of Metabolism on Clinical Scanners | 001 | 1 | NIH | 6/6/2024 | $28,522 |
| 2024 | 2024 | THE GENERAL HOSPITAL CORPORATION | 55 FRUIT ST | BOSTON | MA | 02114-2621 | SUFFOLK | USA | R01EB034197 | Plug-and-play Hyperpolarized MRI of Metabolism on Clinical Scanners | 000 | 1 | NIH | 1/17/2024 | $538,475 |
| 2024 | 2024 | THE GENERAL HOSPITAL CORPORATION | 55 FRUIT ST | BOSTON | MA | 02114-2621 | SUFFOLK | USA | R38AG070229 | MGH Diseases of Aging Pathway Via Stimulating Access to Research in Residency (MGH DAP StARR) | 001 | 2 | NIH | 5/6/2024 | $26,868 |
| 2024 | 2024 | THE GENERAL HOSPITAL CORPORATION | 55 FRUIT ST | BOSTON | MA | 02114-2621 | SUFFOLK | USA | R38AG070229 | MGH Diseases of Aging Pathway Via Stimulating Access to Research in Residency (MGH DAP StARR) | 000 | 2 | NIH | 12/21/2023 | $241,812 |
| 2024 | 2024 | THE GENERAL HOSPITAL CORPORATION | 55 FRUIT ST | BOSTON | MA | 02114-2621 | SUFFOLK | USA | K08CA286755 | A Nurse-Led, Coping and Supportive Care Intervention to Improve Psychosocial Outcomes of Patients with Triple-Negative Breast Cancer During the Transition from Curative Therapy to Surveillance | 000 | 1 | NIH | 7/17/2024 | $251,519 |
| 2024 | 2024 | THE GENERAL HOSPITAL CORPORATION | 55 FRUIT ST | BOSTON | MA | 02114-2621 | SUFFOLK | USA | R01CA288550 | Multi-Site Randomized Controlled Trial of a Novel Digital Application (DREAMLAND) to Improve Outcomes for Patients with Acute Myeloid Leukemia | 000 | 1 | NIH | 7/19/2024 | $591,372 |
| 2024 | 2024 | THE GENERAL HOSPITAL CORPORATION | 55 FRUIT ST | BOSTON | MA | 02114-2621 | SUFFOLK | USA | K08DK132516 | Machine learning-based methods for the analysis of microbial glycomes and proteomes in inflammatory bowel disease. | 000 | 2 | NIH | 11/7/2023 | $169,560 |
| 2024 | 2024 | THE GENERAL HOSPITAL CORPORATION | 55 FRUIT ST | BOSTON | MA | 02114-2621 | SUFFOLK | USA | K08HL168238 | Advancing the clinical actionability of polygenic scores for coronary artery disease | 000 | 1 | NIH | 12/11/2023 | $170,323 |
| 2024 | 2024 | THE GENERAL HOSPITAL CORPORATION | 55 FRUIT ST | BOSTON | MA | 02114-2621 | SUFFOLK | USA | K08HG012811 | Genome-first approach to treatable genetic conditions in adults | 000 | 2 | NIH | 12/8/2023 | $227,362 |
|